| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
1 company
John Hamer last filed a Form 4 in August 2021, as Director at ABCL. John Hamer's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 128,862 shares of ABCL. The ABCL filings lean toward selling, a net 300,000 shares.
John Hamer has 3 Form 4 filings on record from December 2020 to August 2021, all as Director at AbCellera Biologics (ABCL), 2020–2021.
The 7 reported transactions were 2 open-market sales, 2 other transactions, 2 conversions and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $5.1M.
The only open-market sale was 300,000 shares of ABCL at an average $16.94 on September 1, 2021, about $5.1M. Twelve months later ABCL was down 35%.
Shares as reported in the last Form 4 for each company; the most recent is from August 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | ABCL Abcellera Biologics Inc. | Director | Sell | 300,000 | $16.94 | $5,082,252.98 | -70.0% | -11.6% | -34.6% |